NexPoint Real Estate posts $1.12 EPS in Q3 2025, driven by unrealized gains; maintains $0.50 dividend as outlook improves for multifamily and life sciences sectors.
Companies mentioned:
Summary
- NexPoint Real Estate reported a net income of $1.12 per diluted share for Q3 2025, up from $0.74 per diluted share in Q3 2024, driven by unrealized gains on preferred stock and stock warrant investments.
- The company declared a regular dividend of $0.50 per share for both Q3 and Q4 2025, with Q3's dividend being 1.06 times covered by cash available for distribution.
- NexPoint Real Estate's portfolio consists of 88 investments with a total balance of $1.1 billion, heavily weighted towards multifamily and life sciences sectors.
- The company funded $42.5 million in Life Science preferred stock and sold a multifamily property for $60 million, resulting in a $3.7 million gain.
- Guidance for Q4 2025 is set with earnings available for distribution ranging from $0.43 to $0.53 per diluted share, and cash available for distribution ranging from $0.45 to $0.55 per diluted share.
- The company has made significant progress in its Series B Preferred raise, nearing a $400 million offering limit, and is launching a Series C Preferred offering at an 8% coupon.
- NexPoint Real Estate's debt to equity ratio stands at 0.93 times, with a weighted average debt cost of 5.3% and a maturity of 3.9 years.
- Strategically, the company is optimistic about the rental market outlook for 2026, with expected declines in new supply leading to positive revenue growth.
- The life sciences sector shows promise with a long-term lease signed for its Alewife project, enhancing leasing momentum and capital market optionality.
Thank you for standing by. My name is Kate and I will be your conference operator today. At this time I would like to welcome everyone to NexPoint Real Estate for finance Q3 2025 earning call. All lines have been placed on mute to prevent any background noise. After the Speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press STAR followed by the number one on your telephone keypad. If you would like to withdraw your question, press Star one again. Thank you. I would now like to turn the call over to Kristen Griffith, Investor Relations. Please go ahead.
Thank you. Good day everyone and welcome to NexPoint Real Estate Finance Conference call to review the Company's Results for the third quarter ended September 30, 2025. On the call today are Paul Richards, Executive Vice President and Chief Financial Officer, and Matt McGregor, executive vice president and Chief Investment Officer. As a reminder, this call is being webcast through the company's website at nrev.nexpoint.com before we begin, I would like to remind everyone that this conference call contains forward looking statements within the meanings of the Private Securities Litigation Reform act of 1995 that are based on management's current expectations, assumptions and beliefs. Listeners should not place undue reliance on any forward looking statements and are encouraged to review the Company's annual report on Form 10-K and the company's other filings with the SEC for a more complete discussion of risks and other factors that could affect the forward looking statements. The statements made during this conference call speak only as of today's date and except as required by law, NREF does not undertake any obligation to publicly update or revise any forward looking statements. This conference call also includes an analysis of non-GAAP financial measures. For a more complete discussion of these non-GAAP financial measures, see the Company's presentation that was filed earlier today. I would now like to turn the call over to Paul Richards.
Please go ahead Paul Thanks Kristen and welcome everyone. Joining us this morning, I'm going to briefly discuss our quarterly results, move to our balance sheet, and lastly provide guidance for the next quarter before turning it over to Matt for a detailed commentary on the portfolio and the macro lending environment. Third quarter results are as follows. For the third quarter we reported a net income of $1.12 per diluted share compared to net income of $0.74 per diluted share for the third quarter 2024. The increase in net income for the quarter was due to an increase in unrealized gains on preferred stock and stock warrant investments between the third quarter 2025 and the third quarter 2024. Earnings available for distribution was $0.51 per diluted share in Q3 compared to $0.75 per diluted share in the same period of 2024. Cash available for distribution was $0.53 per diluted share in Q3 compared from $0.67 per diluted share in the same period Of 2024. We paid a regular dividend $0.50 per share in the third quarter and the board has declared a dividend of $0.50 per share payable for the fourth quarter of 2025. Our dividend in the third quarter was 1.06 times covered by cash available for distribution. Book value per share increased 8% from Q2 2025 to $18.79 per diluted share, with an increase being primarily due to unrealized gain on our preferred stock investment and stock warrants. During the quarter we funded 42.5 million on a Life Science preferred. During the quarter the company funded 6.5 million on the loan that pays a monthly coupon of Secured Overnight Financing Rate plus 900 basis points. The company sold a multifamily property for $60 million that resulted in a $3.7 million gain and raised 65.7 million in gross proceeds from the Series B preferred stock raise. On October 27, 2025, NexPoint Real Estate Finance announced a fourth quarter dividend of $0.50 per common share moving to the portfolio and balance sheet. Our portfolio is comprised of 88 investments with a total outstanding balance of $1.1 billion. Our investments are allocated across sectors as 47.3% multifamily, 33.9% life sciences, 15.9% single family rental, 1.8% storage and 1.1% marina. Our fixed income portfolio is allocated across investments as follows 27% CMBS B pieces 26.5% mezz loans, 18.6% preferred equity investments, 12.4% revolving credit facilities, 10% senior loans, 4.2% IO strips and 1.3% promissory notes. The assets collateralizing our investments are allocated geographically it falls 28.1% Massachusetts 15.5% Texas 8% Georgia 5.3% California 4.2% Maryland 4.4% Florida with the remainder across states with less than 4% exposure reflecting our heavy preference for Sun Belt markets with Massachusetts and California exposure heavily weighted towards Life Science. The collateral on Our portfolio is 87.4% stabilized with 54.9% loan to value and a weighted average DSCR of 1 point 01 times we have $728.9 million of debt outstanding with a weighted average cost of 5.3%. Our debt is collateralized by 633.2 million of collateral with a weighted average maturity of 3.9 years and a debt to equity ratio of 0.93 times. After the quarter we paid off our $36.5 million senior unsecured notes with the new Senior unsecured note offering of $45 million. The coupon on the new notes is 7.875%, a slight increase in the 7.5% notes we issued in October of 2020 when interest rates were near 0%. The new notes carry a term of two years with the prepayment options providing flexibility in this declining rate environment. We're pleased with this execution and look forward to terming out the remaining senior unsecured notes in 1H26. Lastly, we have been making great strides in our Series B Preferred raise which has almost hit the $400 million offering limit given the heightened demand. We are now in the process of launching a Series C Preferred which will be a $200 million offering at an 8% coupon where we will continue to deploy capital at 400 basis. 400 basis point plus spreads at the cost of this capital Moving to Guidance for the fourth for the fourth quarter we are guiding an Earnings available for distribution and cash available for distribution as follows. Earnings available for our distribution of $0.48 per diluted share at a midpoint with a range of $0.43 on the low end and $0.53 on the high end. Cash available for distribution of $0.50 per diluted share at the midpoint with a range of 45 cents on the low end and 55 cents on the high end. Now I would like to turn it over to Matt for a detailed discussion of the portfolio and markets.